- Daraxonrasib Cuts Death Risk 60% in Phase 3 Pancreatic Cancer Trial The Clinical Trial Vanguard
- Daily pill doubles survival time for pancreatic cancer patients BBC
- Daily pill can double survival time for world’s deadliest cancer, trial shows The Guardian
- ‘Landmark’ pancreatic cancer drug keeps patients alive for twice as long The Washington Post
- Revolution’s pancreatic cancer drug doubles survival, boosts quality of life ETPharma.com